HomeLegal DirectoryFDA AI Drug/Bio Guidance

In effect Limited protection

FDA AI/ML in Drug Development and Manufacturing — Discussion Papers and Framework

United States · FDA Discussion Paper (May 2023); CDER/CBER Draft Guidance (Jan. 2025)

FDA published a framework setting expectations for how drug and biologics companies use AI/ML across drug discovery, clinical trials, postmarket safety surveillance, and manufacturing. The framework signals that AI used in regulatory submissions must be transparent, validated, and reproducible.

Technical detail

FDA CDER/CBER Discussion Paper, 'Using Artificial Intelligence and Machine Learning in the Development of Drug and Biological Products' (May 2023), and follow-on draft guidance, 'Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products' (Jan. 2025), define a risk-based credibility framework for AI models used in regulatory submissions.

Who is protected: Patients enrolled in clinical trials and consumers of AI-developed or AI-manufactured drugs/biologics

Who must comply: Sponsors of drug and biological product applications using AI/ML in development or manufacturing

Key facts

JurisdictionUnited States
LevelFederal
StatusIn effect
Protection strengthLimited protection
Effective date2023-05-10
Enacted2023-05-10
CitationFDA Discussion Paper (May 2023); CDER/CBER Draft Guidance (Jan. 2025)
Enforced byFDA Center for Drug Evaluation and Research; Center for Biologics Evaluation and Research
Private right of actionNo — agency enforcement only
PenaltiesClinical hold; application refusal; manufacturing enforcement actions
Topicshealthcare AI · automated decision-making · AI disclosure and transparency
Last verified2026-06-17
Official sourceFDA Discussion Paper — AI/ML in Drug Development and Manufacturing (May 2023) ↗

More AI rules in United States

Related healthcare AI rules elsewhere

See something wrong or out of date? Submit a correction — every entry must carry a verifiable official source.